1. Home
  2. EDIT vs SMID Comparison

EDIT vs SMID Comparison

Compare EDIT & SMID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDIT
  • SMID
  • Stock Information
  • Founded
  • EDIT 2013
  • SMID 1960
  • Country
  • EDIT United States
  • SMID United States
  • Employees
  • EDIT N/A
  • SMID N/A
  • Industry
  • EDIT Biotechnology: Biological Products (No Diagnostic Substances)
  • SMID Building Materials
  • Sector
  • EDIT Health Care
  • SMID Industrials
  • Exchange
  • EDIT Nasdaq
  • SMID Nasdaq
  • Market Cap
  • EDIT 241.9M
  • SMID 219.4M
  • IPO Year
  • EDIT 2016
  • SMID 1995
  • Fundamental
  • Price
  • EDIT $2.69
  • SMID $39.93
  • Analyst Decision
  • EDIT Buy
  • SMID
  • Analyst Count
  • EDIT 12
  • SMID 0
  • Target Price
  • EDIT $5.40
  • SMID N/A
  • AVG Volume (30 Days)
  • EDIT 1.3M
  • SMID 10.2K
  • Earning Date
  • EDIT 11-03-2025
  • SMID 08-14-2025
  • Dividend Yield
  • EDIT N/A
  • SMID N/A
  • EPS Growth
  • EDIT N/A
  • SMID 162.25
  • EPS
  • EDIT N/A
  • SMID 2.27
  • Revenue
  • EDIT $38,901,000.00
  • SMID $90,998,000.00
  • Revenue This Year
  • EDIT N/A
  • SMID N/A
  • Revenue Next Year
  • EDIT N/A
  • SMID N/A
  • P/E Ratio
  • EDIT N/A
  • SMID $17.52
  • Revenue Growth
  • EDIT N/A
  • SMID 32.97
  • 52 Week Low
  • EDIT $0.91
  • SMID $25.13
  • 52 Week High
  • EDIT $4.12
  • SMID $51.96
  • Technical
  • Relative Strength Index (RSI)
  • EDIT 51.07
  • SMID 48.95
  • Support Level
  • EDIT $2.56
  • SMID $38.92
  • Resistance Level
  • EDIT $2.84
  • SMID $41.81
  • Average True Range (ATR)
  • EDIT 0.17
  • SMID 2.39
  • MACD
  • EDIT 0.00
  • SMID -0.32
  • Stochastic Oscillator
  • EDIT 58.82
  • SMID 57.61

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

About SMID Smith-Midland Corporation

Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.

Share on Social Networks: